Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common form of liver cancer, remains a major public health problem worldwide. The immune microenvironment plays a critical role in regulating tumor progression and resistance to therapy, and in HCC, the tumor microenviron...

Full description

Bibliographic Details
Main Authors:	Zeynep Akbulut, Başak Aru, Furkan Aydın, Gülderen Yanıkkaya Demirel
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma immune checkpoint proteins immune checkpoint inhibition tumor microenvironment anticancer immunity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1379622/full

Similar Items

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia
by: Başak Aru, et al.
Published: (2023-01-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
by: Nicola Personeni, et al.
Published: (2021-11-01)

Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints
by: Xiaoqiang Wang, et al.
Published: (2023-04-01)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
by: Jun Ho Ji, et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Nikolaos Machairas, et al.
Published: (2022-04-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Samantha M. Ruff, et al.
Published: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang JX, et al.
Published: (2022-03-01)

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
by: Landon L. Chan, et al.
Published: (2022-03-01)

Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma
by: Tianhao Cong, et al.
Published: (2022-10-01)

Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma
by: CAO Jiali, et al.
Published: (2023-05-01)

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
by: David Repáraz, et al.
Published: (2022-02-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
by: Hsu HM, et al.
Published: (2023-10-01)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
by: Qingqing Xie, et al.
Published: (2022-09-01)

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
by: Yasuyuki Tamai, et al.
Published: (2023-10-01)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
by: Pei-Chang Lee, et al.
Published: (2020-01-01)

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
by: Matthias Ocker, et al.
Published: (2021-03-01)

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
by: Qimeng Gao, et al.
Published: (2021-12-01)

Advances in Immunotherapy for Hepatocellular Carcinoma
by: Satoru Hagiwara, et al.
Published: (2023-03-01)

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
by: Perla Chami, et al.
Published: (2023-11-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
by: Naoshi Nishida, et al.
Published: (2020-05-01)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
by: Stefania De Lorenzo, et al.
Published: (2022-09-01)

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
by: Ran Qin, et al.
Published: (2023-12-01)

Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy
by: Yanan Wang, et al.
Published: (2022-10-01)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
by: Michela Guardascione, et al.
Published: (2020-08-01)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
by: Tao Sun, et al.
Published: (2023-07-01)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
by: Jingyu Jiang, et al.
Published: (2023-02-01)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
by: Krista Y. Chen, et al.
Published: (2022-10-01)

Mismatch repair gene MSH6 correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer
by: Lin-Zhi Zhou, et al.
Published: (2024-02-01)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
by: Haohao Li, et al.
Published: (2022-12-01)

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
by: Rujia Zhang, et al.
Published: (2023-12-01)

Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma
by: Masahiro Morita, et al.
Published: (2023-04-01)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
by: Jiahui Yu, et al.
Published: (2023-08-01)